Literature DB >> 7378650

Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.

M Baldacci, M Baldacci, T D Bergel, G V Born, M Hickman.   

Abstract

1 Citrated platelet-rich plasma was prepared from New Zealand white rabbits before, during and after administration of chlorpromazine (2 mg/kg) intramuscularly once daily for 3 to 4 weeks. 2 In these plasmas, the velocity of platelet aggregation by 5-hydroxytryptamine (5-HT) added at 1, 3 and 10 microM increased greatly, beginning 3 to 4 days after the start of chlorpromazine injections and lasting for a similar period after they were terminated. The increase had two maxima, the first after 6 to 10 days and the second after 17 to 24 days. Chlorpromazine treatment did not affect aggregation by adenosine diphosphate (ADP). 3 The uptake of 5-HT by rabbit platelets was very fast and linear for less than 10 s. In platelets from untreated rabbits the uptake had a Km of 0.35 +/- 0.08 microM and a Vmax of 39.8 +/- 6.1 pmol 10(-8) platelets 10(-1) (n = 5). 4 In platelets from rabbits injected with chlorpromazine (see (2) above) both kinetic constants increased significantly, the Km to 0.88 +/- 0.08 microM and the Vmax to 67.8 +/- 5.5 pmol. 10(-8) platelets. 10(-1) s (n = 9).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378650      PMCID: PMC2044185          DOI: 10.1111/j.1476-5381.1980.tb10889.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  5-Hydroxytryptamine receptors of platelets.

Authors:  G V Born; F Michal
Journal:  Ciba Found Symp       Date:  1975

Review 2.  Fluid-mechanical and biochemical interactions in haemostasis.

Authors:  G V Born
Journal:  Br Med Bull       Date:  1977-09       Impact factor: 4.291

3.  [Behavior of rat platelets].

Authors:  Z Sinakos; J Caen
Journal:  Thromb Diath Haemorrh       Date:  1966-07-31

4.  Effect of the rapid shape change of platelets on the transmission and scattering of light through plasma.

Authors:  F Michal; G V Born
Journal:  Nat New Biol       Date:  1971-06-16

5.  Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.

Authors:  D J Boullin; H F Woods; R P Grimes; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

6.  Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors.

Authors:  G V Born; R Dearnley; J G Foulks; D E Sharp
Journal:  J Physiol       Date:  1978-07       Impact factor: 5.182

7.  Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.

Authors:  F Michal; M Motamed
Journal:  Br J Pharmacol       Date:  1976-02       Impact factor: 8.739

8.  The relation between the 5-hydroxytryptamine content and aggregation of rabbit platelets.

Authors:  H R Baumgartner; G V Born
Journal:  J Physiol       Date:  1969-04       Impact factor: 5.182

9.  Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.

Authors:  G V Born; K Juengjaroen; F Michal
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

10.  Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors?

Authors:  M Graf; A Pletscher
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

View more
  5 in total

Review 1.  Platelets and neurobiological research.

Authors:  G V Born
Journal:  Experientia       Date:  1988-02-15

2.  The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.

Authors:  M W Orr; J M Knox; R Allen; M G Gelder; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

3.  Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.

Authors:  M B Youdim; A Hefez; B Oppenheim
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 5.  Human platelet 5-hydroxytryptamine receptors: binding of [3H]-lysergic acid diethylamide (LSD). Effects of chronic neuroleptic and antidepressant drug administration.

Authors:  D G Grahame-Smith; D P Geaney; M Schachter; J M Elliott
Journal:  Experientia       Date:  1988-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.